BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Dong-A PharmTech Initiates Approval Process For Zydena In China


11/27/2006 11:24:52 AM

SEOUL, Korea, Nov. 27 /PRNewswire/ -- Dong-A PharmTech Co., Ltd., announced that it initiated the approval process for Zydena, its new erectile dysfunction drug, in China by filing for import verification. The company is expecting to complete the requirements of the Chinese drug regulatory agency (SFDA) which includes a local clinical study, and receive marketing approval by 2008.

China's pharmaceutical market has expanded dramatically in the past decade, and currently valued at over US$25 billion. It has been reported that as many as 50 per cent of Chinese men aged between 40 and 70 are suffering from erectile dysfunction (ED), similar to other countries. Zydena is expected to participate in a growing prescription ED market by offering a long acting and safe product that will compete with Viagra(R) (Pfizer).

Zydena was launched in Korea in December 2005 and has already captured over 20% (by volume) of the market. This rapid uptake in Korea underscores Zydena's high patient satisfaction (up to 85% on satisfaction scores in clinical studies), excellent efficacy up to 12 hours and a favorable safety profile. In Korea, Zydena competes directly with Viagra(R) (Pfizer), Cialis(R) (Lilly) and Levitra(R) (Bayer).

Dong-A PharmTech has recently completed a 340 patient double-blind, placebo controlled phase 2b dose ranging/confirmation study at 15 urology sites in the USA. The results of this study are expected in December 2006.

Mr. Dong-Hyun Park, President & CEO of Dong-A PharmTech stated, "With the recent filing in China we expect to move rapidly to complete the requirements for approval. We believe that China is a growth market for ED drugs, especially Zydena with its good safety profile and patient preferred long acting efficacy."

About Dong-A PharmTech Co., Ltd.

Dong-A PharmTech Co., Ltd. is an affiliate of Dong-A Pharmaceutical Co. Ltd., the largest drug company in Korea. Dong-A PharmTech is developing Zydena(TM) for non-Korean markets.

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to FDA review and approval, product development and acceptance, manufacturing, competition, and/or other factors, which are outside the control of the Company.

Contact: Dr. Dongjin Yoo Dong-A PharmTech Co. Ltd, Tel: +82 2 560 8003, Fax: +82 2 563 6517, Email: dy36@donga.co.kr

Dong-A PharmTech Co., Ltd.

CONTACT: Dr. Dongjin Yoo of Dong-A PharmTech Co. Ltd, +82 2 560 8003, orFax: +82 2 563 6517, or dy36@donga.co.kr



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES